1[1]Bull P,Make B.Acute exacerbations of chronic bronchitis-an international comparison.Chest,1998,113(3):1998～2048
2[2]Sullivan JT,Woodruff M,Lettien J,et al.Pharmacokinetics(PK)and tolerability of the new mothoxyquinolone BAY 12-8039:10 days' treatment at 400mg.8th ECCMID,1997.359
3[3]Heimer-Bau M,Beyer G,Stass H,et al.Pharmacokinetics(PK)and influence of moxifloxacin(MOX)on bacterial intestinal flora in young male subjects.38th ICCAAC,1998.16
4[4]Stass HH,Kubitza D.Study to evaluate the interaction between moxifloxacin(M)and iron supplements(FE)[abstract T154].Anti-infect Drug Chemother,1998,16(1):74
5[5]Stass HH,Kubitza D,Schwietert H,et al.DAY 12-8039 does not interact with theophylline.20th ICC,1997.34
6[6]Stass HH,Halabi A,Delesen H.No dose adjustment is needed for patients with renal impairment receiving oral moxifloxacin.38 th ICAAC,1998.14
7[7]Blouin RA,Hamelin BA,Smith DA,et al.Fleroxacin pharmacokinetics in patients with liver cirrhosis.Antimicrob Agents Chemother,1992,36:632～638
8[8]Loebstein R,Addix A,Ho E,et al.Pregnancy outcome following gestational exposure to fluoroquinolones:a multicenter prospective controlled study.Antimicrob Agents Chemother,1998,42:1336～1339
9[9]Ferguson J,Al-Ajmi R,Kubin R,et al.A double-blind placebo and lomefloxacin controlled human volunteers' phototest study to determine the photosensitising potential of oral moxifloxacin(Day 12-8039).8th ICID,1998.59
10[10]Andrews JM,Honeybourne D,Brenwald NP,et al.Concentrations of trovafloxacin in bronchial mucosa,epithelial lining fluid,alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibreoptic bronchoscopy.J Antimicrob Chemother,1997,39:797～802
